PEspeaks

Feb 10, 2012
Pharmaceutical Executive
A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies, and pressures on the pharmaceutical market have put the brakes on one of the US’s most robust biotechnology centers
Feb 09, 2012
Pharmaceutical Executive
Following the premise that good news needs to be shared, Pharm Exec is proud to announce that one of our sister Advanstar publications, Medical Economics, has been selected as Media Brand of the Year by Medical Marketing and Media (MM&M) magazine.
Feb 08, 2012
Pharmaceutical Executive
Feb 08, 2012
Pharmaceutical Executive
David Torstensson, Senior Consultant, Pugatch Consilium, considers what the London Declaration on Neglected Tropical Diseases reveals about research and development efforts into neglected and tropical diseases.
Feb 08, 2012
Pharmaceutical Executive
Of the 399 senior executives in the life sciences industry surveyed by the Economist Intelligence Unit (EIU) recently, 64% of respondents said that demonstrating value is a key challenge facing their business. The major issue, most agree, is that stakeholders have different perceptions of what value is.
Feb 07, 2012
Pharmaceutical Executive
At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.
Feb 07, 2012
From Pharmaceutical Technology
Last week, FDA Commissioner Margaret A. Hamburg testified before the House Committee on Energy and Commerce, Subcommittee on Health to outline the agency’s case for supporting the fifth authorization of the Prescription Drug User Fee Act (PDUFA), also known as PDUFA V.
Feb 03, 2012
Pharmaceutical Executive
Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Feb 03, 2012
Pharmaceutical Executive
The Healthcare Businesswomen’s Association (HBA) has announced that its 2012 Woman of the Year (WOTY) is Carolyn Buck Luce, global pharmaceutical sector leader at Ernst & Young.
Feb 02, 2012
Pharmaceutical Executive
In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research“
native1_300x100
lorem ipsum